Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Product

  2.3.2 Market Size By Biomarkers

  2.3.3 Market Size By Application

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 List of biomarker and reagent suppliers

3.4.2. List of liquid biopsy assay and diagnostic solution manufacturers

3.4.3. List of laboratory service providers, distributors and testing networks

3.4.4. List of hospitals, oncology centers, diagnostic laboratories and end-users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

 4.1 Product Performance & Adoption Metrics

  4.1.1 Assay Kit Utilization and Testing Volume Trends

4.1.2. Instrument Installation and Laboratory Capacity Expansion Metrics

4.1.3. Diagnostic Service Utilization and Revenue Growth Trends

4.2. Biomarker Detection & Clinical Performance Metrics

4.2.1. Circulating Tumor Cell (CTC) Detection and Analysis Trends

4.2.2. cfDNA Sensitivity, Specificity and Mutation Detection Performance Metrics

4.2.3. Extracellular Vesicle Biomarker Research and Clinical Adoption Trends

4.3. Clinical Application & Patient Management Metrics

4.3.1. Early Detection and Screening Test Adoption Trends

4.3.2. Treatment Selection and Precision Oncology Utilization Metrics

4.3.3. Disease Monitoring and Minimal Residual Disease Assessment Trends

4.4. Laboratory Operations & Healthcare Utilization Metrics

4.4.1. Liquid Biopsy Testing Volume and Turnaround Time Trends

4.4.2. Oncology Center Adoption and Diagnostic Workflow Efficiency Metrics

4.4.3. Cost Reduction and Patient Accessibility Improvement Trends

5. Breast Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Product, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 Assay Kits

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Instruments

 5.4 Services

6. Breast Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Biomarkers, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 Circulating Tumor Cells (CTCs)

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Circulating Cell-Free DNA (cfDNA)

 6.4 Extracellular Vesicles (EVs)

 6.5 Other Circulating Biomarkers

7. Breast Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Application, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Early Detection/Screening

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Diagnosis

 7.4 Treatment Selection

 7.5 Monitoring

8. Breast Cancer Liquid Biopsy Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

8.1 Introduction

8.2 North America

 8.2.1 Key Trends

 8.2.2 Breast Cancer Liquid Biopsy Market Size & Forecast, By Product, 2022–2035

 8.2.3 Breast Cancer Liquid Biopsy Market Size & Forecast, By Biomarkers, 2022–2035

 8.2.4 Breast Cancer Liquid Biopsy Market Size & Forecast, By Application, 2022–2035

 8.2.5 Breast Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035

  8.2.5.1 USA

  8.2.5.2 Canada

8.3 Europe

 8.3.1 Key Trends

 8.3.2 Breast Cancer Liquid Biopsy Market Size & Forecast, By Product, 2022–2035

 8.3.3 Breast Cancer Liquid Biopsy Market Size & Forecast, By Biomarkers, 2022–2035

 8.3.4 Breast Cancer Liquid Biopsy Market Size & Forecast, By Application, 2022–2035

 8.3.5 Breast Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035

  8.3.5.1 Germany

  8.3.5.2 UK

  8.3.5.3 France

  8.3.5.4 Italy

  8.3.5.5 Spain

  8.3.5.6 Russia

  8.3.5.7 Poland

  8.3.5.8 Rest of Europe

8.4 Asia-Pacific

 8.4.1 Key Trends

 8.4.2 Breast Cancer Liquid Biopsy Market Size & Forecast, By Product, 2022–2035

 8.4.3 Breast Cancer Liquid Biopsy Market Size & Forecast, By Biomarkers, 2022–2035

 8.4.4 Breast Cancer Liquid Biopsy Market Size & Forecast, By Application, 2022–2035

 8.4.5 Breast Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035

  8.4.5.1 China

  8.4.5.2 India

  8.4.5.3 Japan

  8.4.5.4 South Korea

  8.4.5.5 Australia

  8.4.5.6 ASEAN Countries

  8.4.5.7 Rest of Asia-Pacific

8.5 Latin America

 8.5.1 Key Trends

 8.5.2 Breast Cancer Liquid Biopsy Market Size & Forecast, By Product, 2022–2035

 8.5.3 Breast Cancer Liquid Biopsy Market Size & Forecast, By Biomarkers, 2022–2035

 8.5.4 Breast Cancer Liquid Biopsy Market Size & Forecast, By Application, 2022–2035

 8.5.5 Breast Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035

  8.5.5.1 Brazil

  8.5.5.2 Argentina

  8.5.5.3 Mexico

  8.5.5.4 Colombia

  8.5.5.5 Rest of Latin America

8.6 Middle East & Africa

 8.6.1 Key Trends

 8.6.2 Breast Cancer Liquid Biopsy Market Size & Forecast, By Product, 2022–2035

 8.6.3 Breast Cancer Liquid Biopsy Market Size & Forecast, By Biomarkers, 2022–2035

 8.6.4 Breast Cancer Liquid Biopsy Market Size & Forecast, By Application, 2022–2035

 8.6.5 Breast Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035

  8.6.5.1 UAE

  8.6.5.2 Saudi Arabia

  8.6.5.3 Qatar

  8.6.5.4 South Africa

  8.6.5.5 Rest of Middle East & Africa

9. Competitive Landscape

 9.1 Key Players' Positioning

 9.2 Competitive Developments

  9.2.1 Key Strategies Adopted (%), By Key Players, 2025

  9.2.2 Year-Wise Strategies & Development, 2022–2025

  9.2.3 Number Of Strategies Adopted By Key Players, 2025

 9.3 Market Share Analysis, 2025

 9.4 Product/Service & Biomarkers Benchmarking

  9.4.1 Product/Service Specifications & Features By Key Players

  9.4.2 Product/Service Heatmap By Key Players

  9.4.3 Biomarkers Heatmap By Key Players

 9.5 Industry Start-Up & Innovation Landscape

9.6 Key Company Profiles

 9.6.1 Guardant Health Inc.

  9.6.1.1 Company Overview & Snapshot

  9.6.1.2 Product/Service Portfolio

  9.6.1.3 Key Company Financials

  9.6.1.4 SWOT Analysis

 9.6.2 Foundation Medicine Inc. (Roche)

9.6.3. Illumina Inc.

9.6.4. Exact Sciences Corporation

9.6.5. Tempus AI Inc.

9.6.6. NeoGenomics Laboratories Inc.

9.6.7. Natera Inc.

9.6.8. GRAIL LLC (Illumina)

9.6.9. Veracyte Inc.

9.6.10. Burning Rock Biotech Ltd.

9.6.11. Berry Oncology Corp.

9.6.12. Inivata Ltd. (NeoGenomics)

9.6.13. Biocept Inc.

9.6.14. CellMax Life Inc.

9.6.15. Menarini Silicon Biosystems SpA

9.6.16. Angle plc

9.6.17. QIAGEN N.V.

9.6.18. F. Hoffmann-La Roche Ltd.

9.6.19. Personalis, Inc.

9.6.20. Lucence Diagnostics Pte. Ltd.

10. Analyst Recommendations

 10.1 SNS Insider Opportunity Map

 10.2 Industry Low-Hanging Fruit Assessment

 10.3 Market Entry & Growth Strategy

 10.4 Analyst Viewpoint & Suggestions On Market Growth

11. Assumptions

12. Disclaimer

13. Appendix

 13.1 List Of Tables

 13.2 List Of Figures